Financial Consulate’s Sagimet Biosciences SGMT Stock Holding History

Financial Consulate’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.5K	Buy	+253	New	+$2.32K	﹤0.01%	1072

Other funds holding SGMT

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

RIA

RPG Investment Advisory Pleasanton, California $540M AUM 37.68% 1-Year Est. Return

T3 Companies New York $103M AUM 54.73% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Physician Wealth Advisors Midvale, Utah $869M AUM 17.6% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Financial Consulate's SGMT Position: Q3 2026 in Review

Financial Consulate opened a new position in Sagimet Biosciences (SGMT) in Q3 2026: 253 shares worth $2.5K. The stake represents ﹤0.01% of the portfolio and ranks #1072 among its holdings.

11 funds tracked by Wall St. Rank hold SGMT as of Q3 2026.

Financial Consulate held 253 shares of Sagimet Biosciences worth $2.5K as of Q3 2026.
Sagimet Biosciences was a new Financial Consulate position in Q3 2026.
Sagimet Biosciences made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1072 holding.
11 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.